Meeting
2020 Genitourinary Cancers Symposium
A phase II, open-label study of durvalumab in combination with stereotactic body radiotherapy in androgen-intact patients with oligometastatic prostate cancer.
Authors
Isobel Porter
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia
Isobel Porter , Thomas Eade , Andrew Kneebone , George Hruby , Sophie Mascall , Alexander P. Davis , Alexander David Guminski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
ACTRN12619000097145
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS263)
Abstract #
TPS263
Poster Bd #
P7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz
Poster
2020 Genitourinary Cancers Symposium
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
First Author: Phuoc T. Tran
Poster
2024 ASCO Genitourinary Cancers Symposium
Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone.
First Author: Jonathan David Tward
Poster
2023 ASCO Annual Meeting
Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.
First Author: Alberto Carretero-González